Document Detail


How to reduce mortality in STEMI patients treated with primary percutaneous coronary interventions: Cut the bleeding.
MedLine Citation:
PMID:  23350949     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Background. In-hospital mortality for ST elevation myocardial infarction (STEMI) has declined thanks to a greater use of primary percutaneous coronary interventions (PCI) associated to more effective antiplatelet and anticoagulant drugs. In this regard, bivalirudin has been shown to decrease total and cardiac mortality as compared to unfractionated heparin (UFH). Objective. The primary purpose of this analysis is to evaluate the hypothesis that the reduction of in-hospital bleeding is the most plausible explanation for the improved survival of STEMI patients treated with bivalirudin during primary PCI. The secondary objective is to reconsider the prognostic significance of the radial access alone or in association with bivalirudin on the basis of the published data. Methods. We have done a comprehensive evaluation of the main and related publications of the HORIZONS-AMI trial in addition to an extensive research by Medline of the randomized trials evaluating the prognostic impact of radial access as compared with the femoral one in primary PCI. Results. In the HORIZONS-AMI trial bivalirudin resulted in a significant lower rates of the 30-day primary endpoint (defined as major adverse ischemic outcomes plus major bleeding) over UFH plus GPI, largely due to the significant lower rate of the protocol defined major bleeding. All-cause and cardiac mortality were also reduced in the bivalirudin arm at 3 years follow-up. Recent studies have also shown that the use of the radial instead of the femoral approach for primary PCI is associated with reduced bleeding as well as reduced mortality. Conclusions. Our research suggests that decreasing bleeding by either a pharmacologic strategy (use of bivalirudin) or a technical approach (the transradial access) improves survival in STEMI patients undergoing primary PCI. The validity of this hypothesis should be confirmed by specific randomized trials.
Authors:
Stefano De Servi; Giuseppe Mariani; Matteo Mariani; Maurizio D'Urbano
Related Documents :
11571239 - Left ventricular muscle mass and elevated heart rate are associated with coronary plaqu...
24985899 - Histopathology of aspirated thrombi during primary percutaneous coronary intervention i...
25110069 - Frequency of angina pectoris and secondary events in patients with stable coronary hear...
24619969 - Long-term safety and efficacy of second-generation everolimus-eluting stents compared t...
23528029 - Previous myocardial infarction as a risk factor for in-hospital cardiovascular outcomes...
24667349 - Serum alanine aminotransferase predicts interventricular septum thickness and left vent...
3769169 - Systemic vascular resistance: an unreliable index of left ventricular afterload.
871349 - Antagonism of morphine with naloxone in dogs: cardiovascular effects with special refer...
12860889 - Anomalous origin of the circumflex artery and patent foramen ovale: a rare cause of myo...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-25
Journal Detail:
Title:  Current medical research and opinion     Volume:  -     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Cardiovascular Diseases, Ospedale Civile di Legnano, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  BRAIN: a universal tool for high-throughput calculations of isotopic distribution for mass spectrome...
Next Document:  Electrocatalytic Water Oxidation with a Copper(II) Polypeptide Complex.